Articles On Telix Pharmaceuticals (ASX:TLX)

The share market dropped 0.8 per cent following pressure on US stocks as the threat of significantly higher interest rates dampened buying interest.   The S&P/ASX 200 declined 58 points to 7165. Tech stocks led a sell-off in sectors...

ShareCafeEvening Report: 1 June, 2022 by Lauren Evans   The Australian sharemarket held on to its gains in the afternoon session despite a big drop in lithium miners. Communication services led the pack up nearly 2 per cent, followed by fin...

Mesoblast reports quarterly trading revenues Telix appoints new executives Osprey restructures business, in trading halt Cellular medicines specialist Mesoblast (ASX:MSB) says its revenues in the third quarter increased by 5% on the same...

ShareCafeLunch Report: 1 June, 2022 by Lauren Evans   The Aussie sharemarket is pushing higher this morning after Wall Street fell overnight amid inflation and recession fears across the globe. Most sectors are showing gains, with the excep...

Telix Pharmaceuticals (TLX) announces a number of changes to its executive leadership team to enable the company to move into its next phase of growth The company has appointed Darren Smith as Chief Financial Officer, replacing Doug Cubbin...

01 Jun 2022 - Darren Smith will take over Doug Cubbin as chief financial officer of Telix Pharmaceuticals (ASX:TLX).

ShareCafeEvening Report: 30 May, 2022 by Lauren Evans   The ASX 200 rose for a second successive day led by technology, materials and bank shares. At the closing bell, the index was 1.5 per cent or 104 points higher at 7,287, its best perfo...

ASX 200 was up 1.3% today, led by Tech which jumped 4% A2M rose 10% after Bubs got  export deal with the US AGL Energy cancels coal demerger plan   A surge in Tech stocks led the ASX to a 1.3% higher close today, following a strong rally...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed Wall Street’s lead and is charging higher. At the time of writing, the benchmark index is up 1.1% to 7,259.6 points. Four ASX shares that are climbing more than most tod...

ShareCafeLunch Report: 30 May, 2022 by Melissa Darmawan   Australian shares jumped to a three week high after a strong lead from Wall St. Every sector is rallying, bar utilities after news from AGL. The optimism is led by technology shares,...

30 May 2022 - A snapshot of the stocks on the move featuring Telix Pharmaceuticals (ASX:TLX), Australian Unity Office Fund (ASX:AOF) & Yancoal (ASX:YAL).

Invion demonstrates high efficacy of INV043 when used as a combined therapy Biotron gets positive feedback from US FDA Biome stocks its Probiotics range on Priceline’s shelves Invion demonstrates efficacy Cancer fighter Invion (ASX:IVX) w...

MELBOURNE, Australia and INDIANAPOLIS, May 30, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on the U.S. and Australian launch and reimbursement status for its prostate cancer i...

Friday has brought good news for embattled investors. DeVere Group CEO and founder Nigel Green has tipped that major global indexes – such as the S&P/ASX 200 Index (ASX: XJO) – could be nearing their lowest point and getting ready to r...

ShareCafeLunch Report: 18 May, 2022 by Melissa Darmawan   Materials lift ASX higher for 4th day Australian shares are on track to continue its winning streak for its fourth straight day after taking a strong lead from Wall St. The local ind...

World Overnight SPI Overnight 7181.00 + 70.00 0.98% S&P ASX 200 7112.50 + 19.50 0.27% S&P500 4088.85 + 80.84 2.02% Nasdaq Comp 11984.52 + 321.73 2.76% DJIA 32654.59 + 431.17 1.34% S&P500 VIX 26.10 – 1.37 – 4.99%...

Australian shares were poised to open higher for a fourth day after strong retail sales doused fears of an economic slowdown in the US.   Wall Street’s main indices closed sharply higher as a rebound from six weeks of steady decline gath...

Australian stocks were poised to open higher as lockdown news out of China over the weekend added to positive leads from Wall Street and commodity markets.   ASX futures rallied 54 points or 0.77 per cent on Friday night as US stocks sur...

Australian shares rebounded strongly this session but could not avert a fourth straight weekly decline as financial markets continued to factor in the risk of a global slowdown as rates rise and China pursues zero-Covid. An end-of-week r...

A relief rally lifted the ASX 200 back above the 7000 level as a pause in this week’s bloodletting on Wall Street brought buyers back to market. The S&P/ASX 200 bounced 95 points or 1.36 per cent to 7036 by mid-session. The rally bro...

You might be sick of hearing this, but turbulent times like now mean it’s more important than ever to retain a long-term view of ASX shares. You might look at a particular stock and be horrified that it has dropped half its value this year...

The share market logged its weakest close since January as the tech sector slumped to a two-year low and the dollar fell below 69 US cents. Borrowing-dependent growth stocks bore the brunt as the S&P/ASX 200 tumbled 124 points or 1.7...

Highlights: Race Oncology is riding high with governance approval for human trial of its new therapy Zantrene®. The cancer drug will be studied in patients with extramedullary Acute Myeloid Leukaemia (AML) or high-risk Myelodysplastic...

Biotechnology ASX shares have been one of the biggest victims of persistent inflation and rising interest rate fears over the past 6 months.  The S&P/ASX 300 Pharmaceuticals & Biotechnology (ASX: AXPBKD) has lost about 15% over tha...

Some of the worst-performing corners of the market enjoyed a day in the sun after a relief rally on Wall Street inspired the ASX’s first advance this week. Gold miners, tech companies and small and micro caps outperformed as the S&P/...

Tech and commodity stocks steered the share market towards its first gain of the week following Wall Street’s best session since 2020. The S&P/ASX 200 overcame an early wobble to advance 44 points or 0.6 per cent by mid-session. T...

MELBOURNE, Australia and INDIANAPOLIS, May 5, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the ‘STARLITE 2’ Phase II study of the Company’s invest...

Highlights Gains in the market were broad-based today with all the 11 individual sectors ending in the positive territory. The IT sector rose 2.25% on Friday followed by Telecom and Consumer Discretionary, which added 1.89% and 1.46% r...

The share market ended a volatile month on a strong note, advancing for a second day ahead of a likely rate rise next week. The S&P/ASX 200 climbed 78 points or 1.06 per cent. The rally trimmed the benchmark’s loss for the month to 6...

A broad rally carried the share market towards a second day of gains at the end of a challenging month for investors. All 11 sectors rose as the S&P/ASX 200 put on 58 points or 0.79 per cent. The advance trimmed the index’s loss for...

The first few months of 2022 has seen share market volatility like we could not even imagine last year. This means that quite a few businesses have seen their stock fall like a stone. Yet their operations and fortunes may not have changed...

A week-long rally soured with the share market’s heaviest loss in two months as investors took profits ahead of the long weekend. The S&P/ASX 200 slumped 119.5 points or 1.57 per cent to its first loss in six sessions. The reversal p...

22 Apr 2022 - Telix Pharmaceuticals (ASX:TLX) reported on its March quarter, with focus placed on its prostate cancer product.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is sliding today and is now 1.96% in the red at $4.51. Investors appear to have been unimpressed by Telix’s quarterly activities and cash flow report today, with trading volume less tha...

The share market backed off an eight-month high after a sharp reversal on Wall Street stoked risk aversion ahead of the long weekend.   The S&P/ASX 200 skidded 124 points or 1.63 per cent by mid-session. The decline ended a five-sess...

A disappointing quarterly from mining heavyweight BHP crimped a fifth day of share market gains as the ASX 200 edged closer to record territory. The Australian benchmark climbed to within 0.5 per cent of last year’s peak, rising 31 point...

ASX 200 healthcare shares have struggled for the past six months, let’s face it. After peaking at 52-week highs of 47,760 back in September 2021, the S&P/ASX 200 Health Care Index (ASX: XHJ) now rests at 39,861. That’s a 16.5% decline...

Aussie shares pared solid early gains as rising rates and stronger-than-expected Chinese consumer prices sharpened global inflation worries ahead of tomorrow’s US data. The S&P/ASX 200 slashed an early 47-point surge to seven points...

11 Apr 2022 - Telix Pharmaceuticals (ASX:TLX) has entered into a licence agreement with Eli Lilly, which grants Telix rights to develop and commercialise radiolabelled forms of Lil…

Telix Pharmaceuticals (ASX:TLX) signs an exclusive licence agreement with Eli Lilly to develop its cancer antibody medication olaratumab Telix will pay Lilly an initial US$5 million (A$6.7 million) for the rights to its radiolabelled forms...

The share market hit a four-session high before turning negative as US futures signalled potential weakness tonight. The S&P/ASX 200 reached mid-session a point or 0.01 per cent lower after earlier gaining 47 points.  The early rally...

MELBOURNE, Australia and INDIANAPOLIS, April 11, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under...

S&P/ASX 200 healthcare index modestly up 0.16% for week Gut health company Microba falls on IPO Rhythm Biosciences bowel cancer blood screening test milestone Have a habit of forgetting where you put your keys or mobile phone? You ma...

MELBOURNE, Australia, April 6, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for p...

Gains in the resources, banking and technology sectors contributed to a 6.9% total return for the ASX200 in March, as Australia continued to outperform global equity markets. -The ASX200 gained 6.9% (total return) during March-Value continu...

Telix Pharmaceuticals (ASX:TLX) has announced that its prostate cancer imaging agent Illuccix, also known as 68Ga-PSMA-11 injection, is now commercially available in the US.

ASX 200 extends winning streak US bonds have sharply inverted, sparking concerns of a potential recession China says it has found a new Omicron sub-variant   It was a sea of green today on the ASX, as local investors shrugged off a rapid...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price took off today after the company released news of its lead product and a $23 million funding package.   Telix’s prostate cancer imaging agent Illuccix is now available for order in the U...

The share market ended within 80 points of this year’s highest close as a mining rally rolled on amid speculation about a commodities “supercycle”. The S&P/ASX 200 rallied 20 points or 0.27 per cent to 7513.7. The index hit its 2022...

A lithium-led mining rally kept the ASX on track for this year’s highs.   The S&P/ASX 200 climbed 22 points or 0.3 per cent by mid-session. The advance lifted the index briefly to within 100 points of this year’s peak. Lithium min...